This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Data regarding short- and long-term complications is included in the IUGA's recommendations to assess the procedure's risk–benefit ratio more effectively. Current investigations into the superiority of using biological grafting versus native tissue or surgical mesh indicate that grafting provides better results.
Green mambas (western, eastern, and Jameson's) are all highly venomous snakes that can be highly aggressive and unpredictable in disposition. They can suddenly go from a state of relative calm to an extremely agitated and dangerous state. All three species have a tendency to strike repeatedly with little provocation, although they are generally much less aggressive than their larger cousin, the black mamba. All three species of green mamba are highly arboreal, alert, extremely quick, and agile. Although the potency of their venom is similar to the more venomous cobra species, mamba venom is much more rapid-acting and the dendrotoxins contained in mamba venom is generally more devastating in nature to the central nervous system, causing more severe neurotoxicity in more rapid fashion. The western green mamba (Dendroaspis viridis) is highly venomous and aggressive with a LD50 of 0.7 mg/kg SC and the average venom yield per bite is approximately 100 mg. The mortality rate of untreated bites is unknown but is thought to be very high (>80%). The eastern green mamba (Dendroaspis angusticeps) has an average venom yield per bite of 80 mg according to Engelmann and Obst (1981). The subcutaneous LD50 for this species ranges from 0.40 mg/kg to 3.05 mg/kg depending on different toxicology studies, authority figures and estimates. The mortality rate of untreated bites is unknown but is thought to be very high (70–75%). Generally the calmest and most shy of the green mamba species, the Eastern green will still strike repeatedly if cornered or agitated.
Resurgence of train ridership in the 21st century pushed the current Pennsylvania Station under Madison Square Garden to capacity, leading to several proposals to renovate or rebuild the station, often characterized as correcting for the 1960s demolition of the original facility. The Times noted in 2025 that a succession of elected officials over several decades—including Governors Pataki, Spitzer, Cuomo, and Hochul—had made gestures at reconstructing the station, though no such reconstruction ultimately materialized. Among the reasons, the Times cited the controlling interests of multiple transit companies—Amtrak, which owns the station, along with NJ Transit and the MTA, which operate within it—and the influence of James Dolan, whose company owns Madison Square Garden and the air rights above the station. Several of the failed plans were entangled with questions of if and how to move the Garden; in 2008, Eliot Spitzer induced the Garden to sign a memorandum of understanding to move one block west as part of a planned station reconstruction, although his plan fizzled after he was felled by a prostitution scandal only a week later. In 2013, the Regional Plan Association and Municipal Art Society formed the Alliance for a New Penn Station, advocating for limiting the extension of Madison Square Garden's operating permit to ten years and soliciting designs to move the arena.
== Leukotrienes in asthma == Leukotrienes contribute to the pathophysiology of asthma, especially in patients with aspirin-exacerbated respiratory disease (AERD), and cause or potentiate the following symptoms:
Sources: en.wikipedia.org
Throughout history there have been wars and conquests that were wide ranging, engulfing whole regions and beyond (so-called "central wars"), at times creating empires which spanned multiple continents, such as through the Mongol conquest. The creation of global maritime empires, as through European colonialism, has been characterized as global conquest, but only the wars between the resulting empires (so-called great powers) have been considered global wars, giving rise to a world wide understanding of conflict and war.
== Contents and curation == Because curation resources are finite, accession policies commonly prioritize poorly represented taxa and geographic areas, legally collected material, authoritative identifications, and specimens that can be housed and made available for study.
Official website Eli Lilly and Company on OpenSecrets, a website that tracks and publishes data on campaign finance and lobbying Hand book of pharmacy and therapeutics, Science History Institute, c. 1919 Business data for Eli Lilly and Company:
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.